NASDAQ:DAWN Day One Biopharmaceuticals Q3 2023 Earnings Report $6.94 +0.33 (+5.02%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Day One Biopharmaceuticals EPS ResultsActual EPS-$0.54Consensus EPS -$0.60Beat/MissBeat by +$0.06One Year Ago EPSN/ADay One Biopharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADay One Biopharmaceuticals Announcement DetailsQuarterQ3 2023Date11/6/2023TimeN/AConference Call DateMonday, November 6, 2023Conference Call Time7:00AM ETUpcoming EarningsDay One Biopharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, July 29, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Day One Biopharmaceuticals Earnings HeadlinesDAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More - NasdaqJuly 8 at 12:42 AM | nasdaq.comWhen Will Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Breakeven?July 1, 2025 | finance.yahoo.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. July 9 at 2:00 AM | Altimetry (Ad)Day One Biopharmaceuticals Inc News (DAWN) - Investing.comJune 24, 2025 | investing.comTimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN)June 23, 2025 | msn.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | finance.yahoo.comSee More Day One Biopharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email. Email Address About Day One BiopharmaceuticalsDay One Biopharmaceuticals (NASDAQ:DAWN) (NASDAQ:DAWN) is a clinical-stage biotechnology company dedicated to developing precision therapies for patients with solid tumors. The company’s research focuses on designing small molecules that target key drivers of cancer growth and survival, including hormone receptors and cell cycle regulators. Its lead candidate, camizestrant, is an oral selective estrogen receptor degrader (SERD) currently in late-stage development for the treatment of estrogen receptor-positive, HER2-negative advanced breast cancer. Beyond its lead program, Day One leverages a proprietary discovery platform to advance additional candidates across multiple oncology targets. Early-stage assets include novel molecules aimed at disrupting oncogenic signaling and DNA damage repair pathways. The company’s pipeline strategy emphasizes differentiated mechanisms of action designed to address areas of high unmet medical need and to overcome resistance to existing therapies. Founded in 2018 and headquartered in San Francisco, Day One Biopharmaceuticals completed its initial public offering in mid-2021. The company maintains research operations in San Diego and supports clinical development through collaboration with trial sites across North America and Europe. This geographic footprint enables Day One to enroll a diverse patient population and to expedite regulatory interactions with health authorities in key markets. Day One’s leadership team is led by Chief Executive Officer David Meek, a seasoned biotech executive with more than two decades of experience in oncology drug development and commercialization. The management team also includes veterans from leading pharmaceutical and biotechnology companies, bringing deep expertise in clinical operations, regulatory affairs, and global commercial planning. Under this guidance, Day One is positioned to advance its pipeline toward potential regulatory approval and to deliver new treatment options for cancer patients.Written by Jeffrey Neal JohnsonView Day One Biopharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Wells Fargo & Company (7/15/2025)Citigroup (7/15/2025)Charles Schwab (7/15/2025)Bank of New York Mellon (7/15/2025)Progressive (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)BlackRock (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.